What Global Clinical Central Lab does

Global Clinical Central Lab (GCCL) is a South Korea-based clinical trial specimen analysis organization operating as a subsidiary of GC Group (GC녹십자). Founded in 2019 and headquartered in Yongin-si, Gyeonggi-do, GCCL provides an integrated one-stop laboratory service spanning Central Lab operations (5,000+ validated test items across hematology, immunology, biochemistry, microbiology, pathology, special biochemistry, and genomics), Bioanalytical Lab services (PK/PD, immunogenicity/ADA/NAb, biomarkers via LBA, FACS, PCR/ddPCR, LC-MS/MS, and ELISpot platforms), and Clinical Support including project management, customized lab kit production, and bio-logistics. The company operates BSL-2 and BSL-3 biocontainment facilities and runs the proprietary G-HUB central lab management system with an integrated LIMS, FDA 21 CFR Part 11-compliant electronic data transfer.

GCCL serves domestic and international pharmaceutical and biotechnology sponsors, global CROs, and academic/research institutions, with documented participation in landmark Korean drug approvals including CuroCell's RIMQARTO (Korea's first domestically developed CAR-T therapy) and GC녹십자's Barythrax anthrax vaccine (Korea's 39th new drug). Customer segments span oncology, cell and gene therapy, central nervous system, and infectious disease clinical trials. The company operates more than 50 direct domestic branches across South Korea for sample collection and cold-chain transport, supported by validated global logistics partners (World Courier, Marken, FedEx), and reports a partner network of 200+ entities across the Asia-Pacific region plus 20+ overseas analysis institutions under MOU/MSA and 20+ global CRO agreements. Full-scope GCLP accreditation from Korea's MFDS, plus ISO 15189, CAP, NGSP Level 1, EQA, and IBBL certifications, underpin eligibility for multinational regulatory submissions. Revenue is generated through project-based professional services contracts priced per analysis, per sample, or as comprehensive service packages across Phase 1 through Phase 4 trials, with no public pricing or revenue disclosure.

Recent strategic emphasis has shifted to global expansion through partnerships with OPIS (Europe-focused), Medicover MICS (US/EU/APAC), and Frontage Laboratories (US/APAC), alongside ecosystem buildout via MoUs with KoNECT, KBIOHealth, and KIMCo Foundation in Korea. GTM relies on direct enterprise sales at major industry conferences (ASCO, BIO International, JPM Healthcare Conference, World Vaccine Congress, BIO KOREA) augmented by webinars, blogs, and KoNECT Korea Pavilion booths. The firm received Frost & Sullivan's 2025 Best Practices Customer Value Leadership Award for the Asia-Pacific clinical trial specimen analysis services industry.

Name

Global Clinical Central Lab

Legal name

주식회사 지씨씨엘 (GCCL Co., Ltd.)

Website

https://gccl.co.kr

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

51–100 employees

Short description

Global Clinical Central Lab (GCCL) is a South Korea-based, GC Group subsidiary that provides integrated GCLP-certified central lab, bioanalytical, and clinical trial specimen analysis services — including PK/PD, biomarker, immunogenicity, and bio-logistics — to pharmaceutical, biotech, and CRO clients across Asia-Pacific, Europe, and the Americas.

Ownership category

akta.pro rank

Product category

Clinical Trial Laboratory Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Scientific Research and Development Services (5417)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE)

akta.pro secondary industries

Central Laboratory Services (Core Lab Operations) (HLAGAEAA), Bioanalytical & PK/PD Sample Analysis (Trial Support) (HLAGAEAG), Data Management, Reporting & Regulatory Submissions for Central Labs (HLAGAEAL), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Clinical Research & Trial Central Laboratories (HLAFAMAL), Lab Data Exchange & Interoperability (HL7/FHIR/LDT Results Delivery) (HLACAMAL)

Keywords

• Clinical trial laboratory
• Central lab services
• Bioanalytical testing
• Pharmaceutical specimen analysis
• Clinical trial logistics

Headquarters

HQ city

Yongin

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Clinical Trial Specimen Analysis Services: GCCL provides integrated professional laboratory services spanning the entire clinical trial lifecycle, including Central Lab operations, bioanalytical services (PK/PD, ADA, NAb, biomarkers), sample logistics, and project management. Revenue is generated through project-based contracts with pharmaceutical and biotech companies, typically priced per analysis, per sample, or as a comprehensive service package. Services cover Phase 1 through Phase 4 clinical trials.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

GCCL provides integrated, GCLP/CAP-accredited clinical trial specimen analysis services spanning the full lifecycle (Phase 1–4). Its offering combines Central Lab (5,000+ safety/efficacy test items), Bioanalytical Lab (PK/PD, ADA/NAb, biomarkers via LBA, FACS, ddPCR, LC-MS/MS, ELISpot), R&D Lab (method development and validation), Clinical Support (project management, customized lab kits, data management), and Bio Logistics (domestic cold-chain with 50+ branches and global courier partners), all unified through the proprietary G-HUB central lab management system.

Product overview

GCCL provides an integrated One-Stop Lab CRO solution combining Central Lab Services (safety testing, sample management, PBMC isolation across 5,000+ items), Bioanalytical Lab Services (PK/PD, biomarker, immunogenicity testing via LBA, FACS, PCR/ddPCR, LC-MS/MS, and ELISpot platforms), Clinical Support (project management, lab kits, data management, bio logistics), and the proprietary G-HUB management system. The company specializes in therapeutic areas including oncology, cell & gene therapy, CNS, and infectious diseases, with capabilities spanning vaccine immunogenicity (including FRNT for RSV neutralizing antibodies), CAR-T therapy support, and biomarker discovery. GCCL's services cover the full clinical trial lifecycle from Phase 1 through Phase 4, supported by global partnerships across Asia-Pacific, Europe, and the Americas.

Differentiator

Problem solved

Functional benefit

Brands

• G-HUB: Proprietary Central Lab Management System - a web-based specimen management system for real-time tracking, sample management, and data integration for clinical trial operations.

Products and services

• Central Lab Services Comprehensive central laboratory services covering over 5,000 safety and efficacy test items (hematology, immunology, biochemistry, microbiology, pathology, special biochemistry, genome analysis), plus sample management, biobanking, and PBMC/BMMC isolation, for pharmaceutical and biotech clinical trial sponsors across Phase 1–4.
• Bioanalytical Lab Services Bioanalytical services for early-phase clinical trials covering PK/PD, biomarker analysis, immunogenicity testing (ADA, NAb), and method development/validation, delivered through integrated LBA, FACS, PCR/ddPCR, LC-MS/MS, and ELISpot platforms with BSL-2/BSL-3 biocontainment, supported by a LIMS.
• Clinical Support Services End-to-end clinical support services spanning project management from contract to closeout, customized lab kit production per visit, validated data management with multi-check verification, and sample logistics for domestic and international transport, integrated with GCCL's Central and Bioanalytical offerings.
• Bio Logistics Services Specialized bio logistics services for temperature-sensitive clinical trial samples, investigational products, infectious substances, and blood products. Capabilities include nationwide Korean cold-chain transport via 50+ direct branches with proprietary vehicles and clinical-trial-dedicated transport boxes, plus door-to-door international forwarding through validated global partners (World Courier, Marken, FedEx).
• G-HUB Central Lab Management System Proprietary web-based central lab management portal for clinical trial sponsors, providing real-time sample tracking, results reporting, lab kit ordering, EDC/EDT validated data transfer, project management, multi-system integration (ERP, analytical instruments, bio logistics, clinical IT), and an AI-powered SOP search, all delivered under FDA 21 CFR Part 11-aligned controls.
• Oncology Clinical Trial Specimen Analysis Specialized analytical services for oncology clinical trials, including PK/PD analysis, anti-drug antibody (ADA) testing, cytokine biomarker analysis, and neutralizing antibody (NAb) testing, supported by FACS, ddPCR, ELISA, Luminex, MSD, and LC-MS/MS platforms and proven via support for Korea's first approved CAR-T therapy (RIMQARTO®).
• Cell & Gene Therapy Clinical Trial Specimen Analysis Comprehensive bioanalytical services for CAR-T and CAR-NK cell and gene therapy development, including immunogenicity analysis (ADA/NAb), PK/PD analysis, FACS-based cell characterization, and qPCR/ddPCR-based vector and gene expression analysis across all development stages.
• CNS Biomarker Analysis Services Central nervous system biomarker analysis services combining mass spectrometry-based and ultra-sensitive immunoassays for CNS biomarkers and PK studies, including high-precision MAO-B activity measurement from platelet-rich plasma (co-developed with NeuroBiogen for Kisuladilin/KDS2010 Alzheimer's trials), delivered under an MOU with Seoul National University CLEVERcns.
• Infectious Disease Clinical Trial Specimen Analysis Bioanalytical services for infectious disease clinical trials covering immunogenicity, cytokine panels, viral burden testing, and sample analysis using BSL-2/BSL-3 biosafety facilities for COVID-19, influenza, tuberculosis, MASH, and hepatitis, including automated Focus Reduction Neutralization Test (FRNT) assay for RSV neutralizing antibody titers validated against WHO International Standard and palivizumab (Synagis®).
• Vaccine Immunogenicity Analysis Services Vaccine immunogenicity analysis services covering Anti-PA IgG and TNA (Toxin Neutralization Assay) method development, validation, and sample analysis from preclinical through Phase 4, with reference support for GC녹십자's anthrax vaccine Barythrax (GC1109) which contributed to Korea's 39th new drug approval.

Quantifiable outcome

• Supported 1,200+ clinical trial projects from 2019 to present
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

Partnerships

22 partnerships are on record, tiered major, core and minor.

• KBIOHealth New Drug Development Support Center (Korea Oson Advanced Medical Industry Promotion Foundation)majorStrategic or Co-development Partner · 12 March 2026GCCL and KBIOHealth signed an MOU to strengthen the linkage between Korea's new drug development ecosystem and clinical trial specimen analysis industry. Collaboration areas include joint research planning, national R&D课题 cooperation, joint education programs, co-marketing, and sharing of domestic and international networks and infrastructure. KBIOHealth provides public research infrastructure while GCCL contributes clinical trial analysis and project execution expertise.
• KIMCo Foundation (Korea Innovative Medicines Consortium)majorStrategic or Co-development Partner · 24 February 2026GCCL and KIMCo Foundation signed an MOU to support early-stage bio-ventures in clinical research and regulatory compliance. The collaboration provides biomarker co-exploration, customized assay development, clinical design consulting, and regulatory consulting (IND success rate improvement) for bio-ventures invested in by KIMCo. This is an industry-led open innovation platform established by 59 Korean pharmaceutical companies and the Korea Pharmaceutical & Bio-pharma Manufacturers Association.
• Medicover Integrated Clinical Services (MICS)coreStrategic or Co-development Partner · 9 February 2026GCCL and MICS signed an MOU to collaborate on multinational clinical trial services covering Europe, the United States, and the Asia-Pacific region. The partnership combines MICS's experience and network in Europe and the U.S. with GCCL's specialized analytical capabilities and project management expertise in the APAC region to enhance cross-regional communication efficiency and operational stability. Key areas include clinical trial operations, sample analysis, project management support, joint marketing, and client development.
• OPIS (Organon & Pharma Integration Services)coreStrategic or Co-development Partner · 14 January 2026GCCL and OPIS signed an MOU at the 44th Annual J.P. Morgan Healthcare Conference 2026 in San Francisco to expand collaboration in the global clinical trial market. The partnership combines GCCL's clinical trial analysis expertise with OPIS's Europe-focused global network to deliver integrated and customized services for biopharmaceutical companies across Europe and Asia. Both aim to generate tangible business synergies through joint global clinical trial services, joint projects, and new business development.
• CLEVERcns (Seoul National University Neuro-Psychiatric Efficacy Evaluation Center)majorStrategic or Co-development Partner · 23 September 2025GCCL and CLEVERcns signed an MOU to promote mutual cooperation in neuro-psychiatric clinical research. Collaboration areas include pre-clinical to clinical linkage in brain disease research, joint development of CNS biomarkers and analytical methods, joint operation of education programs, and joint promotion of end-to-end CNS projects and global expansion. CLEVERcns provides clinical consultation and efficacy evaluation; GCCL leads CNS biomarker and assay development.
• Frontage LaboratoriescoreStrategic or Co-development Partner · 23 September 2025GCCL and Frontage Laboratories signed a strategic MOU to strengthen global clinical trial capabilities, with particular focus on the U.S. and Asia-Pacific regions. The partnership leverages complementary services and networks, enabling GCCL to strengthen its global capabilities while Frontage establishes a more effective APAC clinical trial support structure. Joint clinical trial services, co-marketing, project support, and new business development are planned.
• KoNECT (Korea National Enterprise for Clinical Trials)majorStrategic or Co-development Partner · 29 July 2025GCCL and KoNECT signed an MOU to promote mutual cooperation in clinical research, aiming to enhance quality standards in clinical specimen analysis and strengthen global competitiveness. Cooperation areas include institutional framework for quality enhancement, sharing of domestic and international medical/clinical information, joint education programs, and collaborative domestic and international publicity using KoNECT's network infrastructure.
• GC Labs (GC녹십자의료재단)coreOthersGCCL operates in partnership with GC Labs, drawing on 40 years of laboratory experience. GC Labs conducts diagnostic, medical, and pathological tests required for clinical trials, contributing to GCCL's central lab operations and 5,000+ test items capability.
• GC CellminorOthersListed as a partner company on GCCL's website partner section.
• GC GenomeminorOthersListed as a partner company on GCCL's website partner section.
• C&R Research / C&R SMOminorChannel Partner/ Reseller/ DistributorListed as partner companies on GCCL's website partner section, providing SMO and clinical research services.
• PharmaronminorChannel Partner/ Reseller/ DistributorListed as a partner company on GCCL's website partner section, providing CRO services.
• MediramaminorStrategic or Co-development PartnerListed as a partner company on GCCL's website partner section; collaborated on joint webinar content for FDA oncology expedited programs.
• HUMIC (Future Medicine Research Foundation)minorStrategic or Co-development PartnerListed as a partner company on GCCL's website partner section; collaborated on webinars about drug development trends including immunotherapy and microbiome therapeutics.
• KoNECT (Korea National Enterprise for Clinical Trials)majorChannel Partner/ Reseller/ DistributorListed as a partner company on GCCL's website partner section; organizes Korea Pavilion booths at international conferences (ASCO, BIO International) where GCCL participates.
• Seoul National University Hospital Biomedical Research InstituteminorStrategic or Co-development PartnerListed as a partner company on GCCL's website partner section.
• Seoul National University Hospital CLEVERcnsmajorStrategic or Co-development PartnerListed as a partner company on GCCL's website partner section; formal MOU signed separately for neuro-psychiatric clinical research cooperation.
• ABC LonminorChannel Partner/ Reseller/ DistributorListed as a partner company on GCCL's website partner section.
• NeoNeutraminorChannel Partner/ Reseller/ DistributorListed as a partner company on GCCL's website partner section.
• MediplexusminorChannel Partner/ Reseller/ DistributorListed as a partner company on GCCL's website partner section.
• Kyeongsung UniversityminorOthersListed as a partner company on GCCL's website partner section.
• Global Logistics Partners (World Courier, Marken, FedEx)minorChannel Partner/ Reseller/ DistributorGCCL uses validated global logistics partners including World Courier, Marken, and FedEx for international sample transport, offering door-to-door and inbound/outbound overseas services.

Scale indicators11 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Medpace Holdings: Medpace is a mid-to-large CRO with integrated central laboratory services supporting Phase 1–4 clinical trials, particularly for biotech sponsors. Comparable to GCCL in providing embedded central lab services within a CRO-led clinical trial delivery model.
• ACM Global Laboratories: ACM Global is a mid-sized central lab specializing in clinical trial specimen analysis for pharma and CRO clients with focus on bioanalytical and specialty testing. Comparable in scale and service mix to GCCL, serving a similar mid-market pharma/biotech customer base.
• Pharmaron: Pharmaron is a global CRO/CDMO offering bioanalytical, central lab, and clinical research services across China, US, and UK. Directly comparable to GCCL's bioanalytical and central lab service lines; listed as a partner on GCCL's website.
• ICON Central Laboratories: ICON (formerly PRA Health) operates global central lab and bioanalytical services for clinical trials, with broad geographic coverage and integrated data management. Highly comparable to GCCL in service scope (central lab, bioanalytical, kit logistics, project management) for global pharma clients.
• Eurofins Central Laboratory: Eurofins Central Laboratory provides global central lab, bioanalytical, and specialty testing for clinical trials across multiple therapeutic areas. Directly comparable to GCCL's central lab and bioanalytical services, including safety, biomarker, and specialty assay offerings.
• Frontage Laboratories: Frontage is a US-headquartered CRO with bioanalytical, CMC, and central lab capabilities serving pharma/biotech. Directly comparable to GCCL as a bioanalytical/central lab peer; GCCL has a strategic partnership with Frontage for APAC–US clinical trial collaboration.

Broad incumbents

• Labcorp Drug Development (Fortrea): Fortrea (spun out from Labcorp) operates one of the largest global central lab networks serving multinational Phase 1–4 trials. Comparable to GCCL as a central lab services provider for pharma/biotech, but at substantially larger scale and with worldwide owned infrastructure.
• IQVIA Laboratories: IQVIA's global central lab business provides specimen analysis, bioanalytical, and biomarker services to pharma and biotech sponsors worldwide. Overlaps directly with GCCL's central lab, bioanalytical, and project management offerings for multinational clinical trials.
• SGS Health & Nutrition (SGS Clinical Research): SGS provides central laboratory and bioanalytical services for clinical trials globally as part of a broader testing, inspection, and certification portfolio. Overlaps with GCCL's central lab and bioanalytical offerings but operates as part of a much larger diversified testing business.

Regional players

• Wuxi AppTec Laboratory Testing Division: Wuxi AppTec is a China-based CRO/CDMO with bioanalytical and central lab capabilities serving global pharma, with deep APAC presence. Comparable to GCCL as an APAC bioanalytical/central lab peer but with broader service portfolio and different geographic concentration.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@GlobalClinicalCentralLab
• LinkedInlinkedin.com/company/global-clinical-central-lab

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Global Clinical Central Lab